GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Ibere Pharmaceuticals (NYSE:IBER.U) » Definitions » Other Current Assets

IBER.U (Ibere Pharmaceuticals) Other Current Assets : $0.11 Mil (As of Sep. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Ibere Pharmaceuticals Other Current Assets?

Ibere Pharmaceuticals's other current assets for the quarter that ended in Sep. 2022 was $0.11 Mil.

Ibere Pharmaceuticals's quarterly other current assets declined from Mar. 2022 ($0.19 Mil) to Jun. 2022 ($0.18 Mil) and declined from Jun. 2022 ($0.18 Mil) to Sep. 2022 ($0.11Mil).

Ibere Pharmaceuticals's annual other current assets stayed the same from . 20 ($0.00 Mil) to Dec. 2020 ($0.00 Mil) increased from Dec. 2020 ($0.00 Mil) to Dec. 2021 ($0.24 Mil).


Ibere Pharmaceuticals Other Current Assets Historical Data

The historical data trend for Ibere Pharmaceuticals's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ibere Pharmaceuticals Other Current Assets Chart

Ibere Pharmaceuticals Annual Data
Trend Dec20 Dec21
Other Current Assets
- 0.24

Ibere Pharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Other Current Assets Get a 7-Day Free Trial 0.29 0.24 0.19 0.18 0.11

Ibere Pharmaceuticals Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.


Ibere Pharmaceuticals Other Current Assets Related Terms

Thank you for viewing the detailed overview of Ibere Pharmaceuticals's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Ibere Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
2005 Market Street, Suite 2030, Philadelphia, PA, USA, 19103
Ibere Pharmaceuticals is a blank check company.
Executives
Elaine V Jones director C/O TARGACEPT, INC., 200 EAST FIRST STREET, SUITE 300, WINSTON-SALEM NC 27101
Osagie O Imasogie director, 10 percent owner, officer: Chief Executive Officer
Calvin B. Johnson director 2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Zoltan Kerekes director, 10 percent owner, officer: Chief Operating Officer 2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Louis J. Vollmer director 2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Lisa M. Gray director, 10 percent owner, officer: Chief Financial Officer 2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Henrietta Ukwu director 2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Pipv Capital Llc 10 percent owner 2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103

Ibere Pharmaceuticals Headlines